Intermittent/cyclic etidronate 400 mg/day vs placebo
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low